

**MEKOPHAR CHEMICAL
PHARMACEUTICAL JOINT-STOCK
COMPANY**

Reviewed interim consolidated financial statements
for the six-month period ended 30 June 2025

CONTENTS

| | Page |
|---|---------|
| REPORT OF THE BOARD OF DIRECTORS | 1 – 4 |
| REPORT ON REVIEW OF INTERIM FINANCIAL STATEMENTS | 5 |
| REVIEWED INTERIM CONSOLIDATED FINANCIAL STATEMENTS | |
| Interim consolidated balance sheet | 6 – 9 |
| Interim consolidated income statement | 10 |
| Interim consolidated cash flow statement | 11 – 12 |
| Notes to the interim consolidated financial statements | 13 – 41 |

REPORT OF THE BOARD OF DIRECTORS

The Board of Directors have the pleasure in presenting this report and the Reviewed interim consolidated financial statements of Mekophar Chemical Pharmaceutical Joint-Stock Company and its subsidiary (referred to as "the Company") for the six-month period ended 30 June 2025.

1. General information

The Company includes: Mekophar Chemical Pharmaceutical Joint-Stock Company ("the Parent Company") and a subsidiary is Mekophar Company Limited.

The Parent Company

Mekophar Chemical Pharmaceutical Joint-Stock Company ("the Parent Company") is a joint stock company established in Vietnam, is operating under the Business Registration Certificate No. 0302533156 on 08 February 2002, and the 22st amendment Business Registration Certificate dated 10 June 2025 issued by the Department of Planning and Investment of Ho Chi Minh City.

Charter capital of the Parent Company at 30/06/2025 and at 01/01/2025 is VND 255,458,670,000 equivalent with 25,545,867 shares which have par value of VND 10,000/ share.

The Parent Company's shares are officially traded on the UPCOM market - the stock exchange of unlisted public companies on the Hanoi Stock Exchange with the stock code MKP according to Decision No. 1072/QĐ-SGDHN issued by Hanoi Stock Exchange on 29 December 2017 and the first trading date was 29 January 2018.

According to Business registration certificate, the Parent Company's business activities are:

- Producing medicine, pharmaceutical chemicals and medical substances;
- Producing other foodstuffs not yet classified in any other category;
- Producing non-alcoholic beverages and mineral water;
- Producing wooden crates for packaging;
- Short-time accommodation;
- Other uncategorized specialized wholesale;
- Retail of medication, medical equipment, cosmetic and hygiene products in specialized stores;
- Wholesale of food products;
- Wholesale of beverages;
- Wholesale of other household uncategorized appliances;
- Wholesale of other machines, equipment and spare parts;
- Commercial introduction and promotion;
- Other uncategorized financial services;
- Doing business in real-estate, land use rights of owner, users or leased land;
- Technical inspection and analysis;
- Other professional practice, science and technology;
- Agency, intermediary, auction;
- Wholesale of cloth, garments and footwear;
- Activities of hospitals, health stations;
- Other medical activities not classified in any category;
- Producing cosmetics, soap, detergent, polish and sanitary finished product.

In the period, the main activities of the Company were to manufacture and wholesale medicine, pharmaceutical chemicals and medical substances.

The Parent Company's head office is located at 297/5 Ly Thuong Kiet Street, Phu Tho Ward, Ho Chi Minh City, Vietnam.

REPORT OF THE BOARD OF DIRECTORS

Information about branches

The Parent Company has the following affiliated units:

| No. | Name | Address |
|-----|--|--|
| 1 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company | B26-B28-TT17 Van Quan - Yen Phuc New Urban Area, Ha Dong Ward, Hanoi City, Vietnam |
| 2 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company at Da Nang City | 410 Nguyen Tri Phuong Street, Hoa Cuong Ward, Da Nang City, Vietnam |
| 3 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company | 17A Cach Mang Thang Tam Street, Binh Thuy Ward, Can Tho City, Vietnam |
| 4 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company - Medicine Store 1 | D9-10, 143/1 To Hien Thanh Street, Hoa Hung Ward, Ho Chi Minh City, Vietnam |
| 5 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company | No.1, Alley 69, Yen Xuan Street, Vinh Hung Ward, Nghe An Province, Vietnam |
| 6 | Representative office of Mekophar Chemical Pharmaceutical Joint-Stock Company at Hanoi | BT-2D (16B-3) - 16, Mo Lao New Urban Area, Dai Mo Ward, Hanoi City, Vietnam |

Subsidiary

The Parent Company has 1 subsidiary including:

| Name | Address | Main activities | Ownership ratio | Voting ratio |
|--------------------------|--|---|-----------------|--------------|
| Mekophar Company Limited | Lot I-9-5, Road D2, Saigon Hi-tech Park, Tang Nhon Phu Ward, Ho Chi Minh City, Vietnam | Producing biological products, drugs, cosmetics, functional foods, ... and stem cell banking activities | 100% | 100% |

2. The members of the Board of Directors, the Board of Supervisors, the Board of General Directors and Chief Accountant

The members of the Board of Directors, the Board of Supervisors, the Board of General Directors and Chief Accountant during the six-month period ended 30 June 2025 and as at the date of this report include:

The Board of Directors

| Full name | Position | |
|--------------------------|---------------|-------------------------|
| Mr. Le Anh Phuong | Chairman | |
| Ms. Huynh Thi Lan | Vice Chairman | |
| Ms. Dang Thi Kim Lan | Member | |
| Ms. Phan Thi Lan Huong | Member | |
| Ms. Nguyen Thi Hang | Member | Appointed on 24/04/2025 |
| Mr. Satoshi Kawamura | Member | Resigned on 24/04/2025 |
| Ms. Nguyen Thi Quynh Anh | Member | Resigned on 24/04/2025 |
| Ms. Lu Thi Khanh Tran | Member | Resigned on 24/04/2025 |

The Board of General Directors and Chief Accountant

| Full name | Position | |
|------------------------|-------------------------|-------------------------|
| Ms. Phan Thi Lan Huong | General Director | Appointed on 07/05/2025 |
| Ms. Huynh Thi Lan | Deputy General Director | Appointed on 07/05/2025 |
| Ms. Dang Thi Kim Lan | Deputy General Director | Resigned on 07/05/2025 |
| Mr. Le Anh Phuong | Deputy General Director | |
| Mr. Phan Anh Tai | Chief Accountant | |

REPORT OF THE BOARD OF DIRECTORS

The Board of Supervisors

| Full name | Position |
|----------------------|------------------|
| Mr. Nguyen Viet Luan | Chief Supervisor |
| Mr. Nguyen Ba Khoa | Member |
| Mr. Tran Trung Ngon | Member |

Legal representative

The legal representative of the Parent Company during the six-month period ended 30 June 2025 and at the date of this report is:

| Full name | Nationality | Position |
|------------------------|-------------|------------------|
| Ms. Phan Thi Lan Huong | Vietnamese | General Director |

3. The Company's financial position and operating results

The Company's financial position and its operating result for the six-month period ended 30 June 2025 are reflected in the accompanying interim consolidated financial statements.

4. Events subsequent to the balance sheet date

There have been no significant events occurring after the balance sheet date for the six-month period ended 30 June 2025 which would require adjustments or disclosures to be made in the Notes to the interim consolidated financial statements.

5. Auditors

AFC Vietnam Auditing Company Limited has been appointed to review the Company's interim consolidated financial statements for the six-month period ended 30 June 2025.

6. Statement of the Board of General Directors' responsibility in respect of the interim consolidated financial statements

The Board of General Directors is responsible for preparing the interim consolidated financial statements for the six-month period ended 30 June 2025 which give a true and fair view of the consolidated financial position of the Company, as well as of its consolidated operation results and its consolidated cash flows for the year then ended. In preparing those interim consolidated financial statements, the Board of General Directors is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the interim consolidated financial statements;
- Prepare the interim consolidated financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business; and
- Design, implement and maintain the Company's internal control for prevention and detection of fraud and error to preparation and presentation of the interim consolidated financial statements.

The Board of General Directors is responsible for ensuring that the proper accounting records are kept which disclose, with reasonable accuracy at any time, the financial position of the Company and to ensure that the accounting records comply with the Vietnamese Accounting System. The Board of General Directors is also responsible for managing the assets of the Company and therefore has taken the appropriate measures to prevent and detect frauds and other irregularities.

The Board of General Directors confirmed that the Company has complied with the above requirements in preparing the accompanying interim consolidated financial statements.

REPORT OF THE BOARD OF DIRECTORS

7. Approval of the interim consolidated financial statements

The Board of Directors hereby approves the accompanying interim consolidated financial statements which give a true and fair view of the financial position of the Company as at 30 June 2025, its operation results and cash flows of the Company for the six-month period ended 30 June 2025 in accordance with the Vietnamese Accounting Standards, Vietnamese Accounting System and comply with relevant statutory requirements relating to the preparation and presentation of interim consolidated financial statements.

On behalf of the Board of Directors 



LE ANH PHUONG
Chairman

Ho Chi Minh City, 22 August 2025



Công ty TNHH Kiểm Toán AFC Việt Nam
AFC Vietnam Auditing Co., Ltd.

Thành viên tập đoàn PKF Quốc tế
Member firm of PKF International



No.: 185/2025/BCSXHN-HCM.01387

REPORT ON REVIEW OF INTERIM FINANCIAL STATEMENTS

To: The Shareholders, the Board of Directors and the Board of General Directors
Mekophar Chemical Pharmaceutical Joint-Stock Company

We have reviewed the accompanying interim consolidated financial statements of Mekophar Chemical Pharmaceutical Joint-Stock Company and its subsidiary (referred to as "the Company"), prepared on 22 August 2025, as set out from page 6 to 41, which comprise the Interim Consolidated Balance sheet as at 30 June 2025, the Interim Consolidated Income statement, the Interim Consolidated Cash flow statement for the six-month period ended 30 June 2025 and the Notes to the Interim Consolidated Financial statements.

The Board of General Directors' responsibility

The Board of General Directors of the Company is responsible for the preparation and true, fair presentation of these interim consolidated financial statements of the Company in accordance with the Vietnamese Accounting Standards, Vietnamese Accounting System and comply with relevant statutory requirements for the preparation and presentation of the interim consolidated financial statements and for such internal control as the Board of General Directors of the Company determines is necessary to enable the preparation and presentation of these interim consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on these interim consolidated financial statements based on our review. We conducted our review in accordance with Vietnamese Standards on Review Engagements No. 2410 - Review of Interim Financial information Performed by the Independent Auditor of the Entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim consolidated financial statements do not give a true and fair view, in all material respects, of the interim consolidated financial position of the Company as at 30 June 2025, and of the interim consolidated income statement and their interim consolidated cash flows for the six-month period then ended in accordance with Vietnamese Accounting Standards, Vietnamese Accounting System, and the statutory requirements relevant to the preparation and presentation of interim consolidated financial statements.



PHAM THI NGOC LIEN
Deputy General Director
Audit Practicing Registration Certificate
No. 1180-2023-009-1
Authorized Representative
AFC VIETNAM AUDITING COMPANY LIMITED
Ho Chi Minh City, 22 August 2025

LE HUYNH BAO
Auditor
Audit Practicing Registration Certificate
No. 5449-2021-009-1

INTERIM CONSOLIDATED BALANCE SHEET

As at 30 June 2025

| ITEMS | Code | Notes | 30/06/2025 VND | 01/01/2025 VND |
|---|------------|-------|------------------------|------------------------|
| ASSETS | | | | |
| A - CURRENT ASSETS | 100 | | 896,515,909,652 | 961,166,626,723 |
| I. Cash and cash equivalents | 110 | 5.1 | 85,920,852,776 | 173,723,141,505 |
| 1. Cash | 111 | | 65,920,852,776 | 108,723,141,505 |
| 2. Cash equivalents | 112 | | 20,000,000,000 | 65,000,000,000 |
| II. Short term financial investments | 120 | | 30,946,711,100 | 55,946,711,100 |
| 1. Trading securities | 121 | 5.2 | 10,946,711,100 | 10,946,711,100 |
| 2. Provision for diminution in value of held for trading securities | 122 | | - | - |
| 3. Held-to-maturity investments | 123 | 5.2 | 20,000,000,000 | 45,000,000,000 |
| III. Short-term receivables | 130 | | 66,382,057,089 | 55,649,542,440 |
| 1. Short-term accounts receivable | 131 | 5.3 | 47,619,764,513 | 51,199,264,078 |
| 2. Short-term advances to suppliers | 132 | 5.4 | 18,630,142,178 | 14,743,358,205 |
| 3. Short-term inter-company receivables | 133 | | - | - |
| 4. Construction contract receivables based on progress billings | 134 | | - | - |
| 5. Short-term loan receivables | 135 | | - | - |
| 6. Other short-term receivables | 136 | 5.5 | 12,088,614,713 | 1,492,511,083 |
| 7. Provision for doubtful short-term debts | 137 | 5.6 | (11,956,464,315) | (11,785,590,926) |
| 8. Deficient assets pending resolution | 139 | | - | - |
| IV. Inventories | 140 | 5.7 | 696,609,517,624 | 661,752,997,522 |
| 1. Inventories | 141 | | 726,952,411,485 | 692,095,891,383 |
| 2. Provision for decline inventories | 149 | | (30,342,893,861) | (30,342,893,861) |
| V. Other short-term assets | 150 | | 16,656,771,063 | 14,094,234,156 |
| 1. Short-term prepayments | 151 | 5.8 | 2,869,261,231 | 3,616,182,620 |
| 2. Deductible VAT | 152 | | 10,649,020,785 | 10,366,262,005 |
| 3. Other receivables from State budget | 153 | 5.13 | 3,138,489,047 | 111,789,531 |
| 4. Transactions to buy, resell government bonds | 154 | | - | - |
| 5. Other short-term assets | 155 | | - | - |

INTERIM CONSOLIDATED BALANCE SHEET

As at 30 June 2025

| ITEMS | Code | Notes | 30/06/2025 | 01/01/2025 |
|---|------------|-------|--------------------------|--------------------------|
| | | | VND | VND |
| B - NON-CURRENT ASSETS | 200 | | 648,297,592,714 | 670,428,381,671 |
| I. Long-term receivables | 210 | | - | - |
| 1. Long-term receivables from customers | 211 | | - | - |
| 2. Long-term advances to suppliers | 212 | | - | - |
| 3. Business capital in dependent units | 213 | | - | - |
| 4. Long-term inter-company receivables | 214 | | - | - |
| 5. Long-term loan receivables | 215 | | - | - |
| 6. Other long-term receivables | 216 | | - | - |
| 7. Provision for doubtful long-term debt | 219 | | - | - |
| II. Fixed assets | 220 | | 621,231,160,247 | 641,984,491,212 |
| 1. Tangible fixed assets | 221 | 5.9 | 613,408,161,572 | 634,109,057,541 |
| - Cost | 222 | | 1,043,915,889,176 | 1,041,270,588,673 |
| - Accumulated depreciation | 223 | | (430,507,727,604) | (407,161,531,132) |
| 2. Finance leases fixed assets | 224 | | - | - |
| - Cost | 225 | | - | - |
| - Accumulated depreciation | 226 | | - | - |
| 3. Intangible fixed assets | 227 | 5.10 | 7,822,998,675 | 7,875,433,671 |
| - Cost | 228 | | 14,004,583,139 | 14,004,583,139 |
| - Accumulated depreciation | 229 | | (6,181,584,464) | (6,129,149,468) |
| III. Investment property | 230 | | - | - |
| - Cost | 231 | | - | - |
| - Accumulated depreciation | 232 | | - | - |
| IV. Long-term assets in progress | 240 | | 2,414,610 | 2,414,610 |
| 1. Long-term works in progress | 241 | | - | - |
| 2. Construction in progress | 242 | | 2,414,610 | 2,414,610 |
| V. Long-term financial investments | 250 | | 24,068,960,000 | 24,068,960,000 |
| 1. Investment in subsidiaries | 251 | | - | - |
| 2. Investment in joint ventures, and associates | 252 | | - | - |
| 3. Investments in other entities | 253 | 5.2 | 24,068,960,000 | 24,068,960,000 |
| 4. Provision for diminution in value of long-term financial investments | 254 | | - | - |
| 5. Long-term investments held-to-maturity | 255 | | - | - |
| VI. Other non-current assets | 260 | | 2,995,057,857 | 4,372,515,849 |
| 1. Long-term prepaid expenses | 261 | 5.8 | 2,995,057,857 | 4,372,515,849 |
| 2. Deferred income tax assets | 262 | | - | - |
| 3. Long-term equipment, spare parts for replacement | 263 | | - | - |
| 4. Other non-current assets | 268 | | - | - |
| 5. Goodwill | 269 | | - | - |
| TOTAL ASSETS | 270 | | 1,544,813,502,366 | 1,631,595,008,394 |

INTERIM CONSOLIDATED BALANCE SHEET

As at 30 June 2025

| ITEMS | Code | Notes | 30/06/2025 VND | 01/01/2025 VND |
|--|------------|-------|------------------------|------------------------|
| RESOURCES | | | | |
| C – LIABILITIES | 300 | | 309,116,005,331 | 346,911,001,231 |
| I. Current liabilities | 310 | | 115,336,658,506 | 160,062,623,455 |
| 1. Trade accounts payable | 311 | 5.11 | 33,180,387,893 | 64,249,230,707 |
| 2. Short-term advance from customers | 312 | 5.12 | 46,203,845,068 | 48,805,113,472 |
| 3. Taxes and payables to State budget | 313 | 5.13 | 626,038,071 | 6,431,477,406 |
| 4. Payables to employees | 314 | | 8,173,188,599 | 9,969,744,259 |
| 5. Short-term accrued expenses | 315 | 5.14 | 9,785,999,327 | 9,140,164,106 |
| 6. Short-term inter-company payables | 316 | | - | - |
| 7. Construction contract payables based on progress billings | 317 | | - | - |
| 8. Short-term unrealized revenues | 318 | | - | - |
| 9. Other current payables | 319 | 5.15 | 11,087,135,658 | 11,008,966,658 |
| 10. Short-term loans and finance lease liabilities | 320 | | - | - |
| 11. Provision for short-term payables | 321 | | - | - |
| 12. Bonus and welfare funds | 322 | 5.16 | 6,280,063,890 | 10,457,926,847 |
| 13. Price Stabilization Fund | 323 | | - | - |
| 14. Transactions to buy, resell government bonds | 324 | | - | - |
| II. Long-term liabilities | 330 | | 193,779,346,825 | 186,848,377,776 |
| 1. Long-term trade payables | 331 | | - | - |
| 2. Long-term advance from customers | 332 | | - | - |
| 3. Long-term accrued expenses | 333 | | - | - |
| 4. Inter-company payables on capital | 334 | | - | - |
| 5. Long-term payables to inter-company | 335 | | - | - |
| 6. Long-term unrealized revenues | 336 | 5.17 | 193,779,346,825 | 186,848,377,776 |
| 7. Other long-term payables | 337 | | - | - |
| 8. Long-term loans and finance lease liabilities | 338 | | - | - |
| 9. Convertible bonds | 339 | | - | - |
| 10. Preferred shares | 340 | | - | - |
| 11. Deferred income tax liabilities | 341 | | - | - |
| 12. Provision for long-term payables | 342 | | - | - |
| 13. Science and technology development fund | 343 | | - | - |

INTERIM CONSOLIDATED BALANCE SHEET

As at 30 June 2025

| ITEMS | Code | Notes | 30/06/2025 VND | 01/01/2025 VND |
|---|------------|-------|--------------------------|--------------------------|
| D - OWNER'S EQUITY | 400 | | 1,235,697,497,035 | 1,284,684,007,163 |
| I. Capital | 410 | 5.18 | 1,235,697,497,035 | 1,284,684,007,163 |
| 1. Owners' invested capital | 411 | | 255,458,670,000 | 255,458,670,000 |
| - Ordinary shares with voting rights | 411a | | 255,458,670,000 | 255,458,670,000 |
| - Preferred shares | 411b | | - | - |
| 2. Capital surplus | 412 | | 409,789,114,458 | 409,789,114,458 |
| 3. Convertible bonds option | 413 | | - | - |
| 4. Other owner's capital | 414 | | - | - |
| 5. Treasury shares (*) | 415 | | (14,487,151,158) | (14,487,151,158) |
| 6. Assets revaluation difference | 416 | | - | - |
| 7. Foreign exchange difference | 417 | | - | - |
| 8. Investment and development funds | 418 | | 581,829,844,305 | 578,599,664,283 |
| 9. Business arrangements support fund | 419 | | - | - |
| 10. Other owner's funds | 420 | | - | - |
| 11. Retained earnings | 421 | | 3,107,019,430 | 55,323,709,580 |
| - Retained earnings brought forward | 421a | | 32,591,059,015 | 14,538,459,309 |
| - Retained earnings for the current year | 421b | | (29,484,039,585) | 40,785,250,271 |
| 12. Construction capital sources | 422 | | - | - |
| 13. Non-controlling shareholder profit | 429 | | - | - |
| II. Non-business expenditure fund and other funds | 430 | | - | - |
| 1. Non-business expenditure fund | 431 | | - | - |
| 2. Non-business expenditure fund invested in fixed assets | 432 | | - | - |
| TOTAL RESOURCES | 440 | | 1,544,813,502,366 | 1,631,595,008,394 |

LE THI THU HUONG
Preparer

PHAN ANH TAI
Chief Accountant



PHAN THI LAN HUONG
General Director
Ho Chi Minh City, 22 August 2025

INTERIM CONSOLIDATED INCOME STATEMENT

For the six-month period ended 30 June 2025

| ITEMS | Code | Notes | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---|------|-------|---|---|
| 1. Revenues from sale of goods and rendering of services | 01 | | 427,289,520,505 | 469,888,972,134 |
| 2. Deductions | 02 | | 92,845,934 | - |
| 3. Net revenue from sale of goods and rendering of services (10 = 01 - 02) | 10 | 6.1 | 427,196,674,571 | 469,888,972,134 |
| 4. Cost of goods sold | 11 | 6.2 | 323,477,516,470 | 332,245,496,027 |
| 5. Gross profit from sale of goods and rendering of services (20 = 10 - 11) | 20 | | 103,719,158,101 | 137,643,476,107 |
| 6. Financial income | 21 | 6.3 | 4,397,484,733 | 2,419,745,048 |
| 7. Financial expenses | 22 | 6.4 | 1,654,719,131 | 3,425,713,043 |
| - In which: Interest expenses | 23 | | - | - |
| 8. Profit or loss of joint venture and associate | 24 | | - | - |
| 9. Selling expenses | 25 | 6.5 | 56,398,289,732 | 58,656,241,956 |
| 10. General and administration expenses | 26 | 6.6 | 79,858,305,700 | 68,882,454,417 |
| 11. Operating profit/(loss) {30 = 20 + (21 - 22 + 24) - (25 + 26)} | 30 | | (29,794,671,729) | 9,098,811,739 |
| 12. Other income | 31 | 6.7 | 360,310,246 | 44,734,842 |
| 13. Other expenses | 32 | 6.8 | 49,678,102 | 420,623,046 |
| 14. Other profit/(loss) (40 = 31 - 32) | 40 | | 310,632,144 | (375,888,204) |
| 15. Accounting profit before tax (50 = 30 + 40) | 50 | | (29,484,039,585) | 8,722,923,535 |
| 16. Current corporate income tax expense | 51 | 5.13 | - | 1,864,198,403 |
| 17. Deferred corporate income tax expense | 52 | | - | - |
| 18. Net profit after corporate income tax (60 = 50 - 51 - 52) | 60 | | (29,484,039,585) | 6,858,725,132 |
| 19. Profit after tax of shareholders of the parent company | 61 | | (29,484,039,585) | 6,858,725,132 |
| 20. Profit after tax of non-controlling shareholders | 62 | | - | - |
| 21. Earnings per share | 70 | 6.9 | (1,167) | 271 |

LE THI THU HUONG
Preparer

PHAN ANH TAI
Chief Accountant



PHAN THI LAN HUONG
General Director
Ho Chi Minh City, 22 August 2025

INTERIM CONSOLIDATED CASH FLOW STATEMENT

(Indirect method)

For the six-month period ended 30 June 2025


| ITEMS | Code | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|-----------|---|---|
| I. CASH FLOW FROM OPERATING ACTIVITIES | | | |
| 1. Net profit before tax | 01 | (29,484,039,585) | 8,722,923,535 |
| 2. Adjustments for: | | | |
| - Depreciation and amortisation of fixed assets, investment property | 02 | 23,553,752,420 | 23,797,449,633 |
| - Provisions, (reversal) | 03 | 170,873,389 | 6,425,829,284 |
| - (Gain), loss foreign exchange rate differences upon revaluation of monetary | 04 | (486,300,466) | 913,898,567 |
| - Gain, loss from investing activities | 05 | (2,756,058,451) | (1,943,186,320) |
| - Interest expense | 06 | - | - |
| - Other adjustments | 07 | - | - |
| 3. Operating profit before movements in working capital | 08 | (9,001,772,693) | 37,916,914,699 |
| - (Increase), decrease in receivables | 09 | (14,287,536,745) | (6,901,334,982) |
| - (Increase), decrease in inventories | 10 | (34,856,520,102) | (103,229,352,572) |
| - Increase, (decrease) in account payable (other than interest payables, CIT payables) | 11 | (24,847,115,081) | 47,003,313,630 |
| - (Increase), decrease in accrued expenses | 12 | 2,124,379,381 | 2,913,262,888 |
| - Increase, decrease in trading securities | 13 | - | - |
| - Interest paid | 14 | - | - |
| - Corporate income tax paid | 15 | (9,346,477,406) | (8,690,008,085) |
| - Other cash inflows | 16 | 1,410,000 | - |
| - Other cash outflows | 17 | (10,639,633,000) | (3,417,305,456) |
| Net cash flow from operating activities | 20 | (100,853,265,646) | (34,404,509,878) |
| II. CASH FLOW FROM INVESTING ACTIVITIES | | | |
| 1. Cash outflow for purchasing and construction of fixed assets and other long-term assets | 21 | (2,800,421,455) | (6,984,988,371) |
| 2. Proceeds from disposal of fixed assets and other long-term assets | 22 | 22,727,273 | 1,929,090,908 |
| 3. Cash outflow for buying debt instruments of other entities | 23 | (167,233,726,033) | (170,833,589,845) |
| 4. Cash recovered from lending, selling debt instruments of other companies | 24 | 192,233,726,033 | 125,833,589,845 |
| 5. Investment in other entities | 25 | - | - |
| 6. Cash recovered from investments in other entities | 26 | - | - |
| 7. Interest income received, dividends received | 27 | 2,808,021,589 | 2,255,426,689 |
| Net cash flow from investing activities | 30 | 25,030,327,407 | (47,800,470,774) |
| III. CASH FLOW FROM FINANCIAL ACTIVITIES | | | |
| 1. Proceeds from issuing stocks, receiving capital from owners | 31 | - | - |
| 2. Capital withdrawals, buying treasury shares | 32 | - | - |
| 3. Proceeds from short-term borrowings | 33 | - | - |
| 4. Repayment of borrowings | 34 | - | - |
| 5. Repayment of obligations under finance lease | 35 | - | - |
| 6. Dividends paid | 36 | (12,634,110,500) | (12,634,110,500) |
| Net cash flow from financing activities | 40 | (12,634,110,500) | (12,634,110,500) |

INTERIM CONSOLIDATED CASH FLOW STATEMENT

(Indirect method)

For the six-month period ended 30 June 2025

| ITEMS | Code | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|------|---|---|
| NET INCREASE/ DECREASE IN CASH IN THE PERIOD (50 = 20 + 30 + 40) | 50 | (88,457,048,739) | (94,839,091,152) |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR | 60 | 173,723,141,505 | 130,060,029,110 |
| Effects of changes in foreign exchange rate | 61 | 654,760,010 | (616,100,004) |
| CASH AND CASH EQUIVALENTS AT THE END OF YEAR (70 = 50 + 60 + 61) | 70 | 85,920,852,776 | 34,604,837,954 |



LE THI THU HUONG
Preparer



PHAN ANH TAI
Chief Accountant



PHAN THI LAN HUONG
General Director
Ho Chi Minh City, 22 August 2025

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

1. BUSINESS HIGHLIGHTS

1.1 Structure of ownership

Mekophar Chemical Pharmaceutical Joint-Stock Company ("the Parent Company") is a joint stock company established in Vietnam, is operating under the Business Registration Certificate No. 0302533156 on 08 February 2002, and the 22st amendment Business Registration Certificate dated 10 June 2025 issued by the Department of Planning and Investment of Ho Chi Minh City.

Charter capital of the Parent Company at 30/06/2025 and at 01/01/2025 is VND 255,458,670,000 equivalent with 25,545,867 shares which have par value of VND 10,000/ share.

The Parent Company's shares are officially traded on the UPCOM market - the stock exchange of unlisted public companies on the Hanoi Stock Exchange with the stock code MKP according to Decision No. 1072/QĐ-SGDHN issued by Hanoi Stock Exchange on 29 December 2017 and the first trading date was 29 January 2018.

The Parent Company's head office is located at 297/5 Ly Thuong Kiet Street, Phu Tho Ward, Ho Chi Minh City, Vietnam.

1.2 Scope of operating activities

The Company (include the Parent Company and its subsidiary) operates in the field of production, trading, rendering services.

1.3 Line of business

According to Business registration certificate, the Parent Company's business activities are:

- Producing medicine, pharmaceutical chemicals and medical substances;
- Producing other foodstuffs not yet classified in any other category;
- Producing non-alcoholic beverages and mineral water;
- Producing wooden crates for packaging;
- Short-time accommodation;
- Other uncategorized specialized wholesale;
- Retail of medication, medical equipment, cosmetic and hygiene products in specialized stores;
- Wholesale of food products;
- Wholesale of beverages;
- Wholesale of other household uncategorized appliances;
- Wholesale of other machines, equipment and spare parts;
- Commercial introduction and promotion;
- Other uncategorized financial services;
- Doing business in real-estate, land use rights of owner, users or leased land;
- Technical inspection and analysis;
- Other professional practice, science and technology;
- Agency, intermediary, auction;
- Wholesale of cloth, garments and footwear;
- Activities of hospitals, health stations;
- Other medical activities not classified in any category;
- Producing cosmetics, soap, detergent, polish and sanitary finished product.

In the period, the main activities of the Company were to manufacture and wholesale medicine, pharmaceutical chemicals and medical substances.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

1.4 Normal business cycle

Business cycle of the Company is not exceeding 12 months.

1.5 The structure of the Company

The Company includes the Parent Company, 1 direct subsidiary is Mekophar Company Limited.

The Parent Company has the following affiliated units:

| No | Name | Address |
|----|--|--|
| 1 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company | B26-B28-TT17 Van Quan - Yen Phuc New Urban Area, Ha Dong Ward, Hanoi City, Vietnam |
| 2 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company at Da Nang City | 410 Nguyen Tri Phuong Street, Hoa Cuong Ward, Da Nang City, Vietnam |
| 3 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company | 17A Cach Mang Thang Tam Street, Binh Thuy Ward, Can Tho City, Vietnam |
| 4 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company - Medicine Store 1 | D9-10, 143/1 To Hien Thanh Street, Hoa Hung Ward, Ho Chi Minh City, Vietnam |
| 5 | Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company | No.1, Alley 69, Yen Xuan Street, Vinh Hung Ward, Nghe An Province, Vietnam |
| 6 | Representative office of Mekophar Chemical Pharmaceutical Joint-Stock Company at Hanoi | BT-2D (16B-3) - 16, Mo Lao New Urban Area, Dai Mo Ward, Hanoi City, Vietnam |

Subsidiary

The Parent Company has 1 subsidiary which is reflected in the interim consolidated financial statements using the equity method, detail as follows:

| Name | Address | Main activities | Ownership ratio | Voting ratio |
|--------------------------|--|---|-----------------|--------------|
| Mekophar Company Limited | Lot I-9-5, Road D2, Saigon Hi-tech Park, Tang Nhon Phu Ward, Ho Chi Minh City, Vietnam | Producing biological products, drugs, cosmetics, functional foods, ... and stem cell banking activities | 100% | 100% |

According to Resolution No. 22/NQ-DHDCD dated 4 February 2025 of the General Meeting of Shareholders of Mekophar Chemical Pharmaceutical Joint-Stock Company (Parent Company), the policy of merging Mekophar Company Limited (the subsidiary) into the Parent Company has been approved by shareholders. At the time of issuing this report, the subsidiary is still carrying out the merger procedures.

1.6 Declaration on the comparability of information on the interim consolidated financial statements

The figures are presented in the interim consolidated financial statements for the six-month period ended 30 June 2025 compared with the corresponding figures prior period.

1.7 Employees

As at 30 June 2025, the total number of employees of the Company was 633 (31 December 2024: 651 persons).

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

2. ACCOUNTING YEAR AND ACCOUNTING CURRENCY

2.1 Fiscal year

The fiscal year of the Company is from January 01 to December 31 annually.

2.2 Accounting currency

The Company maintains its accounting records in Vietnamese dong (VND) due to the collect and spending are made primarily by currency VND.

3. ACCOUNTING STANDARDS AND REGULATIONS APPLICATION

3.1 Accounting Standards and regulations application

The Company's interim consolidated financial statements are prepared and presented in accordance with Vietnamese Accounting System issued Circular No. 200/2014/TT-BTC on 22 December 2014, the Circular No. 53/2016/TT-BTC on 21 March 2016, the Circular No. 202/2014/TT-BTC on 22 December 2014 issued by the Ministry of Finance guiding the preparation and presentation methods of the interim consolidated financial statements and Vietnam Accounting Standards.

The Company applied Vietnamese accounting standards; Accounting System issued Circular No. 200/2014/TT-BTC, No. 53/2016/TT-BTC, No. 202/2014/TT-BTC and other circulars guiding the implementation of accounting standards by the Ministry of Finance in the preparation and presentation of interim consolidated financial statements.

3.2 Comply with the Vietnamese Accounting Standards and Vietnamese Accounting System

The Board of General Directors is ensure that complied with the Vietnamese Accounting Standards, Vietnamese Accounting System according to Circular No. 200/2014/TT-BTC, Circular No. 53/2016/TT-BTC, Circular No. 202/2014/TT-BTC and as well as the guiding implementation of Vietnamese Accounting Standards issued by the Ministry of Finance in relating to the preparation and presentation of interim consolidated financial statements.

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

4.1 Basis of preparation the interim consolidated financial statements

The interim consolidated financial statements include the financial statements of the Parent Company and the financial statements of subsidiaries controlled by the parent company until the date of the annual report. The control is achieved when the parent company has the ability to control the financial and operating policies of investee companies to obtain benefits from the activities of these companies.

Operating results of subsidiaries which acquired or disposed during the year are presented in the consolidated statement of operations from the date of purchase or to the date of sale of investments in those subsidiaries.

In case of necessity, the financial statements of subsidiaries are adjusted to the accounting policies applied in the parent company and its subsidiaries are the same.

All transactions and balances between companies in the Company are eliminated on consolidation of financial statements.

Non-controlling interest in net assets of consolidated subsidiaries are identified as a target separately from the equity component of the shareholders of the parent company. Interests of non-controlling shareholders include the value of the benefit of non-controlling shareholders as at the initial business combination and share the interests of non-controlling shareholders in the volatility of the total equity since the date of incorporation most business. The losses corresponding to the capital of non-controlling shareholders exceed their share of equity in the total equity of the subsidiary are charged against the interests of the Company unless the non-controlling shareholders have a binding obligation and have the ability to offset such losses.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

Business consolidation

Assets, liabilities and contingent liabilities of the subsidiaries are determined under the fair value at the acquisition date. Any additional terms of the cost of acquisition below the fair value of identifiable net assets acquired is recorded as goodwill. Any deficiency of the cost of acquisition and the fair value of total assets acquired is recognized in the results of operations of the accounting period incurred acquisition activity.

Non-controlling interest at the date of the original business combination is determined on the basis of the percentage of non-controlling shareholders in the total fair value of assets, liabilities and contingent liabilities recognized.

4.2 Accounting Estimates

The preparation of interim consolidated financial statements in accordance with Vietnamese Accounting Standards, the Vietnamese Accounting System and the relevant statutory requirements relating to the preparation and presentation of interim consolidated financial statements requires that the Board of General Directors must make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements as well as the reported amounts about revenues and expenses over the year of operation. Although accounting estimates are made with all known knowledge of the Board of General Directors, actual amounts incurred may differ from estimates, assumptions.

4.3 Foreign currency transactions

In the period, transactions in currencies other than VND during the year have been translated into VND at exchange rates ruling at the date of the transaction. The balances of monetary items denominated in foreign currencies at the period end date are converted by the buying transfer exchange rate and selling exchange rate of the commercial bank which the Parent Company and its subsidiaries have often transactions prevailing on this date.

Exchange differences arising during the year from transactions in foreign currencies are recognized in the financial income or financial expense. Exchange differences arising from revaluation of monetary items denominated in foreign currencies at the balance sheet date after off-setting the differences is recognized in the financial income or financial expense.

4.4 Cash and cash equivalents

Cash comprises cash on hand, cash in banks (demand deposits) and cash in transit. Cash equivalents are short-term highly liquid investments with an original maturity of three months or less which are readily convertible into known amounts of cash and which are subject to an insignificant risk of change in value at the report date.

4.5 Financial investments

Trading securities

Trading securities include stocks and bonds listed on the stock market; securities and other financial instruments held for trading purposes (including securities bought and sold for profit with a maturity of more than 12 months).

Trading securities are recorded at cost, including: Purchase price plus purchase costs (if any) such as brokerage expense, transaction expense, information provision, taxes, and banking fees. The original price of trading securities is determined according to the fair value of the payments at the time of the transaction. Trading securities are recorded at the time when investors have ownership, specifically: Listed securities are recognized at the time of order matching (T+0) and unlisted securities are recorded at the time of official ownership in accordance with the law.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

Provision for devaluation in value of trading securities is made for possible loss in value when there is firm evidence of the market value of those securities held by the Company for trading purposes at the time of preparation of the financial statements.

Held-to-maturity investments

Investments are classified as held to maturity when the Company has the intention and ability to hold to maturity. Investments held to maturity include: bank deposits with a term (including treasury bills, promissory notes), bonds, the preferred shares which issued compulsory acquisition at a certain point in the future and loans held to maturity for the purpose of collecting interest periodically and other held to maturity investments.

Investments held to maturity are initially recognized at cost including purchase price and the expenses related to the purchase of investments. After initial recognition, these investments are stated at recoverable value. Interest income from investments held to maturity after the acquisition date is recognized in the Income statement on an accrual basis. Rates enjoyed before the holding is deducted from the cost of acquisition.

When there is strong evidence suggesting that part or all of the investments may not be recoverable and the damage can be measured reliably, the loss is recorded in financial expenses in the period and reduced directly to investment value.

When an investment is liquidated, the difference between the net disposal proceeds and the carrying amount is recognized as income or expense.

Investments in other entities

Investments in other entities are investments in equity instruments of another entity but the Company does not have control, joint control or significant influence over the investee.

These investments are initially recognized at cost, which includes the purchase price or capital contribution plus any directly attributable costs of the investment. The Board of Management reviews these investments to recognize any provision at the end of the accounting period.

Provisions for loss of investments in equity instruments of other entities are made as follows:

- For an investment in listed shares or the fair value of the investment is reliably determined, the provision is based on the market value of the shares.
- For investments whose fair value cannot be determined at the time of preparing financial statements, provision is made based on the investee's loss with an allowance equal to the difference between the actual contributed capital of the investee and the investor multiplied by the Company's capital contribution ratio compared to the total actual contributed capital of the parties in the other entity.

Increase or decrease in provision for diminution in value of investments in other entities have recorded at the end of the fiscal year, and is recognized in the financial expense.

4.6 Receivables

Trade and other receivables are stated at cost less provision for doubtful debts.

The classifications of receivables are trade receivables and other receivables, which complied with the following principles:

- Trade receivables reflect the nature of the receivables arising from commercial transactions with purchase - sale between the Company and an independent purchaser.
- Other receivables reflect the nature of the receivables arising from non-commercial transactions, and not to be related to the purchase – sale transactions.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

The provision for doubtful debts represents the estimated loss due to non-payment arising on receivables that were outstanding at the balance sheet date. Increases and decreases to the provision balance are recognized as general and administrative expense in the Consolidated Income statement.

4.7 Inventories

Inventories are stated at the lower of cost and net realisable value.

Cost of inventories is determined as follows:

- Materials, goods: comprising all costs of purchase and related expenses directly incurred in bringing the inventories to their present location and condition.
- Finished goods: comprising costs of raw materials, direct labor and general production costs directly related to the production process.
- Work-in-process: including raw materials expenses, direct labor and production expenses.

Net realisable value means the estimated selling price of inventories in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

The Company applies the perpetual inventory method of accounting for inventories and the cost is determined on the weighted average method.

Provision for decline of inventories is made for each inventory with the cost greater than the net value realizable.

An inventory provision is created for the estimated loss arising due to the impairment (through diminution, damage, obsolescence, etc.) of raw materials, finished goods and other inventories owned by the Company, based on appropriate evidence of impairment available at the balance sheet date. Increases and decreases to the provision balance are recognised as cost of goods sold in the consolidated income statement.

4.8 Prepaid expenses

Prepaid expenses include actual expenses incurred but related to the results of production and business activities of many financial years. Prepaid expenses have been put into use and are amortised to expense under the straight-line method to amortise time not exceeding 3 years.

4.9 Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation.

The historical cost of tangible fixed assets include all the expenses that the Company incurs to get fixed assets by the time the asset is put into a state ready for use. Costs incurred after initial recognition is only recorded as increase in cost of fixed assets if these costs are sure to increase economic benefits in the future by using this assets. The costs incurred are not satisfied conditions are recognized as an expense in the period.

When selling or liquidating assets, their cost and accumulated depreciation of the assets are written off in the financial statements and any gain or loss which are arising from disposal are recorded in the Consolidated income statement.

Depreciation of tangible fixed assets which is calculated under the straight-line depreciation method with useful time of the asset is estimated as follows:

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

| | Years |
|-------------------------|---------|
| Building and structure | 05 – 45 |
| Machinery and equipment | 03 – 12 |
| Transportation | 05 – 10 |
| Office equipment | 04 – 10 |

4.10 Intangible fixed assets

Intangible fixed assets are stated at cost less accumulated depreciation.

The historical cost of intangible fixed assets include all the expenses that the Company incurs to get fixed assets by the time the asset is put into a state ready for use. Costs related to intangible assets incurred after initial recognition are recognized as expenses in the period, unless these costs are associated with an intangible asset and increase economic benefits from these assets.

When assets are sold or retired, their cost and accumulated depreciation are removed from the balance sheet and any gain or losses resulting from their disposal are recognized in other income or other expense.

The Company's intangible fixed assets include:

Copyright of stem cells usage

All the actual costs that the Company spent related directly to copyright of stem cells usage. The copyright of stem cells usage of the Company is amortised in 3 years.

Land use rights

Land use rights are all the actual costs that the Company spent related directly to the land use, includes: money spent to have the right to use land, compensation and site clearance expense, leveling, registration fee,... The land use right of the Company is stated at cost and are not amortized depreciation.

Computer software

The expenses of purchasing computer software, which is not a part associated with the relevant hardware, will be capitalised. The initial cost of computer software includes all the expenses paid until the date the software is put into use. Computer software is amortised according to straight –line method in 2 - 5 years.

4.11 Construction in progress

Construction in progress presents costs that are directly related (including related interest expenses in accordance with the Company's accounting policy) to assets under construction, machinery and equipment being installed for production, leasing and management purposes as well as costs related to the repair of fixed assets in progress. These assets are stated at cost and are not depreciated.

4.12 Accounts payables and accrued expenses

Accounts payable and accrued payable are recognized for amounts to be paid in the future, which are related to the goods and services received. Accrued payables are recorded based on reasonable estimates of the amounts payable.

The classification of liabilities is trade payable, accrued expenses and other payables are in accordance with the following principles:

- Trade payables reflects the payables occurring from the commercial transactions with purchase of goods, services, property and the seller, which is an independent unit with the Company.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

- Accrued payables reflect the amounts payable for goods and services received from the seller or has provided to the buyer but not paid due to no or insufficient billing records, accounting records and payable to employees on sabbatical salary, production costs that must be accrued.
- Other payables reflect the payables from non-commercial payables and not relate to the purchase – sale transactions.

4.13 Salary

Salary expenses are determined based on salary, wage and allowances as stated in agreed-upon labor contracts.

4.14 Salary deduction

Social insurance is deducted base on salary under labor contract at a cost of 17.5% and deducted from employees' salaries 8%.

Health insurance is deducted base on salary under labor contract at a cost of 3% and deducted from employees' salaries 1.5%.

Unemployment insurance is deducted base on salary under labor contract at a cost of 1% and deducted from employees' salaries 1%

Trade unions fees deducted on salaries to the cost of 2%.

4.15 Unrealized revenue

Unrealized revenue is an advance revenue mainly consisting of prepayments from customers for one or more accounting periods for asset leasing.

The Company recognizes unrealized revenue in proportion to the obligations that the Company will have to perform in the future. When the revenue recognition conditions are met, unrealized revenue is recognized in the income statement for the period corresponding to the portion that satisfies the revenue recognition condition.

4.16 Owners' equity

Contributed capital of the owner

Capital is recorded according to the amount actually invested by shareholders.

Surplus of stock capital

Surplus of stock capital are recognized at the difference between the issued price and face value of shares when first released, the release added, the difference between the price reissued and the book value of treasury shares and structures the capital of the convertible bond at maturity. Direct expenses related to the issuance of additional shares and treasury shares reissued are reduced Surplus of stock capital.

Treasury shares

Upon the acquisition of the Company's issued shares, the payment includes transaction costs recognized as treasury shares and reflected as a deduction in the owners' equity. When reissued, the difference between the reissue value and the book value of the treasury shares is recorded as "Surplus of stock capital".

Funds

Funds are appropriated and used in accordance with the Charter of the Parent Company.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

4.17 Profit distribution

Profit after corporate income tax is distributed to shareholders after the deduction of funds under the Charter of the Parent Company and the provisions of the law which were approved by the General Meeting of Shareholders.

The distribution of profits to shareholders is considered non-monetary assets and liabilities in net undistributed profit may affect cash flow and ability to pay dividends as profit from revaluation of assets contributed as capital and interest due to the revaluation of monetary items, the financial instruments and non-monetary items other.

Dividends are recognized as liabilities when approved by the General Meeting of Shareholders.

4.18 Earnings per share

Basic earnings per share amount is computed by dividing net profit for the year attributable to ordinary equity holders of the Parent Company before any appropriation of bonus and welfare fund by the weighted average number of ordinary shares outstanding during the year.

4.19 Revenues

Revenues from sales of goods

Revenues from sales shall be recognized if it simultaneously meets the following five (5) conditions:

- (a) The Company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer;
- (b) The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;
- (c) Revenues from sales has been determined with relative certainty. When the contract states that the buyer is entitled to return the purchased products and goods under specific conditions, the Company can only recognize revenue when those specific conditions no longer exist and the buyer is not entitled to return the product ((except for return in the form of exchange for other goods or services);
- (d) The Company has gained or will gain economic benefits from the good sale transaction;
- (e) It is possible to determine the costs related to the goods sale transaction.

Property rental revenue

Property rental revenue is recognized on the principle of allocating the rental amount received in advance in accordance with the rental period

Revenues from rendering services

The revenue of transaction related to the provision of services is recorded when the result of the transaction can be measured reliably. In case that the services are to be provided in many accounting periods, the determination of sales in each period is done on the basis of the service completion rate as of the balance sheet date. The result of this transaction can be measured reliably when satisfy all four conditions:

- (a) Revenue can be measured reliably. When the contract stipulates that the buyer is entitled to return the purchased service under specific conditions, the Company is only recognized when those specific conditions no longer exist and the buyer is not entitled to return the provided service;
- (b) It is possible to obtain economic benefits from the service provision transaction;
- (c) The work volume finished on the date of making the accounting balance sheet can be determined;
- (d) The costs incurred from the service provision transaction and the costs of its completion can be determined.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

Financial income

Income from interest, Distributed dividends and profit are determined on basic:

- Interest is recognized on an accrual basis, are determined on the balance of cash in bank and the actual interest rate for each period.
- Distributed dividends and profit are recognized when the Company is entitled to receive dividends or profit from the capital contribution. Dividends received in shares only track the number of shares increases, no recognition of the value of shares received.

4.20 Operating lease

An operating lease is a lease that the lessor still has most of rights and has to bear the risk relating to the ownership of the asset. Operating lease expense is recognized in the income statement that incurred during the lease term under the straight line method based on the lease term of the contract.

4.21 Corporate income tax

Corporate income tax expenses for the year comprises only current income tax.

Current income tax

Current income tax is the tax amount is calculated on taxable income. Taxable income is different from accounting profit due to the adjustments of temporary differences between accounting and tax, non-deductible expenses as well as adjusted income are not taxed and losses be transferred.

Tax settlement of the Parent Company and a subsidiary will be assessed by the Tax Department. Due to the application of laws and regulations on taxes for different incurred transactions which can be explained in many different ways, tax payable presented in the financial statements can be immediately changed according to the decision of the tax authorities.

4.22 Segment reporting

A business segment is a distinguishable component that is engaged in providing a product or service and that has its own risks and returns which are different from those of other business segments.

A geographical segment a distinguishable component that is engaged in providing a product or services in a particular economic environment and that has its own risks and returns which are different from of segment operating in other economic environment.

4.23 Financial instrument

Financial assets

The classification of financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Financial assets of the Company include cash and cash equivalents, customer receivables and other receivables.

At the time of initial recognition, financial assets are determined at cost plus any costs directly transaction of such financial assets.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

Financial liabilities

The classification of financial liabilities depends on the nature and purpose of the financial liabilities and is determined at the time of initial recognition. Financial liabilities of the Company include payable to suppliers, accrued expenses and other payables.

At the time of initial recognition, except for financial liabilities related to financial leasing and convertible bonds are recorded at cost allocation, other financial liabilities are determined at cost plus costs directly transaction of such financial liabilities.

Amortized cost is determined by the value of the initial recognition of financial liabilities minus principal repayments, plus or minus the cumulative amortization of interest calculated at the actual interest rate method of the difference between the value initially recognized and the maturity value, minus deductions (directly or through the use of a provision) by reducing the value or by irrevocable.

The real interest method is a method of calculating the amortized cost of one or a Company of financial liabilities and amortizing the interest income or interest expense in the relevant period. Real interest rate is the interest rate discounting the cash flows estimated to be paid or received in future during the expected lifetime of the financial instrument or a shorter, if necessary, return to the current book value net financial liabilities.

Owner's equity instruments

Owner's equity instruments are contracts that prove benefits remaining about asset of Company after deducting all of its obligation.

Offsetting of financial instruments

The financial assets and financial liabilities are offset and the net amount is presented on the balance sheet, and if only:

- The Company has the legal right to offset the values were recognized, and
- It intends to pay on a net basis or recognized assets and paid liabilities at the same time.

4.24 Related parties

The parties are related if having the ability to control or significant influence across the decision making of financial policies and operations. Parties are also considered to be related if they are subjected to common control or common significant influences.

The following individuals/ companies are considered as related parties:

| Individuals / Company | Location | Relationship |
|--|----------|---------------------|
| Vietnam Pharmaceutical Corporation | Vietnam | Shareholder |
| Nipro Pharma Corporation | Japan | Shareholder |
| An Sinh Hospital Joint Stock Company | Vietnam | Other related party |
| Orchids Trading Service Travel Company Limited | Vietnam | Other related party |
| The Board of Directors, the Board of Supervisors, the General Director | | Key members |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

5. ADDITIONAL INFORMATION TO ITEMS IN THE INTERIM CONSOLIDATED BALANCE SHEET

5.1 Cash and cash equivalents

| | 30/06/2025 VND | 01/01/2025 VND |
|----------------------|-----------------------|------------------------|
| Cash on hand | 1,466,279,296 | 3,986,531,268 |
| Cash in banks | | |
| - VND | 57,121,390,498 | 86,710,182,150 |
| - USD (a) | 743,637,292 | 790,826,890 |
| - EUR (a) | 25,867,419 | 22,530,607 |
| - JPY (a) | 6,563,678,271 | 17,213,070,590 |
| Cash equivalents (b) | 20,000,000,000 | 65,000,000,000 |
| | 85,920,852,776 | 173,723,141,505 |

(a) Detail of balance of cash in bank by foreign currency as at 30 June 2025, as follows:

| | Foreign currency | Equivalent VND |
|--------------|------------------|-------------------|
| Cash in bank | | |
| - USD | 28,672.38 | 743,637,292 |
| - EUR | 858.59 | 25,867,419 |
| - JPY | 36,793,981.00 | 6,563,678,271 |

(b) Cash equivalents are deposits with a term of no more than 3 months deposited at commercial banks with interest rates according to each deposit contracts.

5.2 Financial investments

Financial investments of the Company include trading securities, held-to-maturity investments and investments in other entitles. Information about financial investments of the Company is as follows:

5.2.1 Trading securities

| | 30/06/2025 | | | 01/01/2025 | | |
|--|-----------------------|------------------|-------------------|-----------------------|------------------|-------------------|
| | Cost VND | Provision VND | Fair value VND | Cost VND | Provision VND | Fair value VND |
| Stock | | | | | | |
| Vidipha Central Pharmaceutical JSC (*) | 4,070,000,000 | - | 7,992,000,000 | 4,070,000,000 | - | 7,992,000,000 |
| OPC Pharmaceutical JSC (*) | 241,461,100 | - | 1,100,178,800 | 241,461,100 | - | 1,100,178,800 |
| Pharmaceutical Packaging JSC | 6,635,250,000 | - | (**) | 6,635,250,000 | - | (**) |
| | 10,946,711,100 | - | | 10,946,711,100 | - | |

(*) The fair value of trading securities is determined according to the closing prices on 30 June 2025 and 31 December 2024 of the Ho Chi Minh Stock Exchange.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

- (**) As at 30 June 2025 and 01 January 2025, the Company has not determined the fair value of these investments to disclose in the Notes to the financial statements, because there is no listed price on the market and Vietnamese accounting standards, the Vietnamese enterprise accounting regime. There is currently no guidance on how to calculate fair value and use valuation techniques. The fair value of these investments may differ from the carrying amount.

5.2.2 Held-to-maturity investments

| | 30/06/2025 | | 01/01/2025 | |
|-------------------|-----------------------|---------------------------|-----------------------|---------------------------|
| | Cost VND | Carrying amount VND | Cost VND | Carrying amount VND |
| Short-term | | | | |
| Term deposit | 20,000,000,000 | 20,000,000,000 | 45,000,000,000 | 45,000,000,000 |
| | 20,000,000,000 | 20,000,000,000 | 45,000,000,000 | 45,000,000,000 |

They are deposits with a term of 6 months deposited at commercial banks with interest rates according to each deposit contracts.

5.2.3 Investments in other entities

| | 30/06/2025 | | | 01/01/2025 | | |
|---|-----------------------|------------------|-------------------|-----------------------|------------------|-------------------|
| | Cost VND | Provision VND | Fair value VND | Cost VND | Provision VND | Fair value VND |
| An Sinh Hospital Joint Stock Company (a) | 18,518,960,000 | - | (*) | 18,518,960,000 | - | (*) |
| Orchids Trading Service Travel Company Limited (b) | 5,550,000,000 | - | (*) | 5,550,000,000 | - | (*) |
| | 24,068,960,000 | - | | 24,068,960,000 | - | |

- (a) This is an investment into An Sinh Hospital Joint Stock Company with an ownership and voting rate of 18.34% on the charter capital of this company. An Sinh Hospital Joint Stock Company was established in Vietnam, operating under Business Registration Certificate No. 0302774433 dated 25 November 2002, the 18th amendment certificate dated 05 July 2022 issued by the Department of Planning and Investment of Ho Chi Minh City. An Sinh Hospital Joint Stock Company's charter capital is VND 134,400,000,000. This company's principal activities are the operations of hospitals and clinics.

- (b) This is an investment into Orchids Trading Service Travel Company Limited Company with an ownership and voting rate of 15% on the charter capital of this company. Orchids Trading Service Travel Company Limited was established in Vietnam, operating under Business Registration Certificate No. 0312680625 dated 10 March 2014 issued by the Department of Planning and Investment of Ho Chi Minh City. Orchids Trading Service Travel Company Limited's charter capital is VND 37,000,000,000. This company's principal activities are short-term accommodation, restaurants, and mobile catering services.

- (*) As at 30 June 2025 and 01 January 2025, the Company has not determined the fair value of these investments to disclose in the Notes to the financial statements, because there is no listed price on the market and Vietnamese accounting standards, the Vietnamese enterprise accounting regime. There is currently no guidance on how to calculate fair value and use valuation techniques. The fair value of these investments may differ from the carrying amount.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

5.3 Short-term accounts receivables

| | 30/06/2025 VND | 01/01/2025 VND |
|--|-----------------------|-----------------------|
| Trade receivables – related parties | | |
| An Sinh Hospital Joint Stock Company | 353,467,528 | 216,144,129 |
| Orchids Trading Service Travel Company Limited | 1,567,500,000 | - |
| Nipro Pharma Corporation | 4,904,812,357 | - |
| Trade receivables – other parties | | |
| Customers at Mekophar Hanoi Branch | 7,501,328,649 | 11,103,963,889 |
| Customers at Mekophar Can Tho Branch | 739,409,113 | 2,929,847,786 |
| Other customers | 32,553,246,866 | 36,949,308,274 |
| | 47,619,764,513 | 51,199,264,078 |

5.4 Short-term advances to suppliers

| | 30/06/2025 VND | 01/01/2025 VND |
|---|-----------------------|-----------------------|
| Advances to other suppliers | | |
| Kim Linh Phat Corporation Joint Stock Company | 1,064,250,000 | 1,064,250,000 |
| Truiking Technology Limited | 3,080,298,000 | 3,080,298,000 |
| Zhejiang Dongying Pharmaceutical Co., Ltd | 3,224,340,000 | - |
| Global Law Company Limited | 4,722,222,222 | - |
| Other suppliers | 6,539,031,956 | 10,598,810,205 |
| | 18,630,142,178 | 14,743,358,205 |

5.5 Other short-term receivables

| | 30/06/2025 | | 01/01/2025 | |
|--|-----------------------|--------------------|----------------------|--------------------|
| | Amount VND | Provision VND | Amount VND | Provision VND |
| Receivables - other individual, organizations | | | | |
| Deposit interest | 512,295,890 | - | 586,986,301 | - |
| Advances | 150,000,000 | - | - | - |
| Remuneration for non- management members of the Board of Directors | 192,000,000 | - | 408,000,000 | - |
| Insurance and trade union receivables | - | - | 421,306,383 | - |
| Collaterals, deposits | 10,725,072,740 | - | - | - |
| Other receivables | 509,246,083 | (8,109,200) | 76,218,399 | (8,109,200) |
| | 12,088,614,713 | (8,109,200) | 1,492,511,083 | (8,109,200) |

5.6 Bad debts

| | 30/06/2025 | | | 01/01/2025 | | |
|---|---------------|------------------------------|------------------|---------------|------------------------------|------------------|
| | Cost VND | Recoverable amount VND | Provision VND | Cost VND | Recoverable amount VND | Provision VND |
| Trade receivables | | | | | | |
| Tan Tao Industrial Zone Branch (Zuellig) | 9,385,514,766 | - | (9,385,514,766) | 9,385,514,766 | - | (9,385,514,766) |
| Other customers | 1,743,882,931 | 447,647,879 | (1,296,235,052) | 1,913,808,527 | 749,474,416 | (1,164,334,111) |
| Advances to suppliers | | | | | | |
| Kim Linh Phat Corporation Joint Stock Company | 1,064,250,000 | - | (1,064,250,000) | 1,064,250,000 | - | (1,064,250,000) |
| Other suppliers | 202,355,297 | - | (202,355,297) | 202,355,297 | 38,972,448 | (163,382,849) |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

| | 30/06/2025 | | | 01/01/2025 | | |
|--------------------------|-----------------------|--------------------|-------------------------|-----------------------|--------------------|-------------------------|
| | Cost | Recoverable amount | Provision | Cost | Recoverable amount | Provision |
| | VND | VND | VND | VND | VND | VND |
| Other receivables | | | | | | |
| Other customers | 16,218,400 | 8,109,200 | (8,109,200) | 16,218,400 | 8,109,200 | (8,109,200) |
| | 12,412,221,394 | 455,757,079 | (11,956,464,315) | 12,582,146,990 | 796,556,064 | (11,785,590,926) |

5.7 Inventories

| | 30/06/2025 | | 01/01/2025 | |
|-----------------|------------------------|-------------------------|------------------------|-------------------------|
| | Cost VND | Provision VND | Cost VND | Provision VND |
| Raw materials | 536,783,733,490 | - | 510,861,347,215 | - |
| Tools | 1,928,695,638 | - | 2,002,022,258 | - |
| Work-in-process | 51,893,269,714 | - | 53,864,503,102 | - |
| Finished goods | 136,004,737,109 | (30,342,893,861) | 125,013,305,169 | (30,342,893,861) |
| Goods | 341,975,534 | - | 354,713,639 | - |
| | 726,952,411,485 | (30,342,893,861) | 692,095,891,383 | (30,342,893,861) |

Movements of provision in the period are as follows:

| | From 01/01/2025 to 30/06/2025 VND | 2024 VND |
|-------------------------|---|-------------------------|
| Opening balance | (30,342,893,861) | (19,109,206,649) |
| Provision in the period | - | (11,233,687,212) |
| Ending balance | (30,342,893,861) | (30,342,893,861) |

5.8 Short-term, long-term prepaid expenses

5.8.1 Short-term prepaid expenses

| | 30/06/2025 VND | 01/01/2025 VND |
|---|----------------------|----------------------|
| Major repair of fixed assets, machinery spare parts | 671,905,763 | 1,131,615,399 |
| Insurance expense | 608,908,810 | 1,586,551,354 |
| Annual calibration fee for machinery and equipment | 646,433,414 | 202,476,778 |
| Land rental expenses | 637,709,244 | - |
| Tools and equipment expenses | 174,865,418 | 396,603,772 |
| Other prepaid expenses | 129,438,582 | 298,935,317 |
| | 2,869,261,231 | 3,616,182,620 |

5.8.2 Long-term prepaid expenses

| | 30/06/2025 VND | 01/01/2025 VND |
|---|----------------------|----------------------|
| Major repair of fixed assets, machinery spare parts | 2,447,380,453 | 3,631,253,432 |
| Calibration and maintenance expenses | 120,000,009 | 200,000,007 |
| Tools and equipment expenses | 357,379,895 | 500,331,851 |
| Other prepaid expenses | 70,297,500 | 40,930,559 |
| | 2,995,057,857 | 4,372,515,849 |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

5.9 Increase, decrease of tangible fixed assets

| | Building and structure VND | Machinery and equipment VND | Transportation VND | Office equipment VND | Total VND |
|---------------------------------|----------------------------------|-----------------------------------|-----------------------|----------------------------|--------------------------|
| HISTORICAL COST | | | | | |
| At 01/01/2025 | 560,932,958,611 | 400,840,609,732 | 16,045,387,731 | 63,451,632,599 | 1,041,270,588,673 |
| Purchase in the period | - | 1,089,921,455 | - | 1,710,500,000 | 2,800,421,455 |
| Liquidation | - | (155,120,952) | - | - | (155,120,952) |
| At 30/06/2025 | 560,932,958,611 | 401,775,410,235 | 16,045,387,731 | 65,162,132,599 | 1,043,915,889,176 |
| ACCUMULATED DEPRECIATION | | | | | |
| At 01/01/2025 | 110,904,280,653 | 228,701,504,750 | 14,612,009,838 | 52,943,735,891 | 407,161,531,132 |
| Depreciation in the period | 7,259,266,104 | 14,733,267,150 | 242,635,542 | 1,266,148,628 | 23,501,317,424 |
| Liquidation | - | (155,120,952) | - | - | (155,120,952) |
| At 30/06/2025 | 118,163,546,757 | 243,279,650,948 | 14,854,645,380 | 54,209,884,519 | 430,507,727,604 |
| NET BOOK VALUE | | | | | |
| At 01/01/2025 | 450,028,677,958 | 172,139,104,982 | 1,433,377,893 | 10,507,896,708 | 634,109,057,541 |
| At 30/06/2025 | 442,769,411,854 | 158,495,759,287 | 1,190,742,351 | 10,952,248,080 | 613,408,161,572 |

The historical cost of fully depreciated tangible fixed assets but still in use as at 30 June 2025 are VND 183,147,706,784 (as at 31 December 2024: VND 182,943,867,736).

5.10 Increase, decrease of intangible fixed assets

| | Land use right VND | Copyright, computer software VND | Total VND |
|---------------------------------|-----------------------|--|-----------------------|
| HISTORICAL COST | | | |
| At 01/01/2025 | 7,438,152,000 | 6,566,431,139 | 14,004,583,139 |
| Increase in the period | - | - | - |
| At 30/06/2025 | 7,438,152,000 | 6,566,431,139 | 14,004,583,139 |
| ACCUMULATED DEPRECIATION | | | |
| At 01/01/2025 | - | 6,129,149,468 | 6,129,149,468 |
| Depreciation in the period | - | 52,434,996 | 52,434,996 |
| At 30/06/2025 | - | 6,181,584,464 | 6,181,584,464 |
| NET BOOK VALUE | | | |
| As at 01/01/2025 | 7,438,152,000 | 437,281,671 | 7,875,433,671 |
| As at 30/06/2025 | 7,438,152,000 | 384,846,675 | 7,822,998,675 |

The historical cost of fully depreciated tangible fixed assets but still in use as at 30 June 2025 are VND 6,069,101,139 (as at 31 December 2024: VND 6,069,101,139).

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

5.11 Trade accounts payable

| | 30/06/2025 | | 01/01/2025 | |
|--|-----------------------|------------------------------|-----------------------|------------------------------|
| | Amount VND | Payment capability VND | Amount VND | Payment capability VND |
| Payables – related parties | | | | |
| Nipro Pharma Corporation | - | - | 855,467,480 | 855,467,480 |
| Payables – other parties | | | | |
| Sinopharm Weiqida Phar | - | - | 15,330,600,000 | 15,330,600,000 |
| Sinobright Pharmaceutical | - | - | 2,693,075,400 | 2,693,075,400 |
| Suheung Vietnam Company Limited | 3,484,447,200 | 3,484,447,200 | 3,783,996,000 | 3,783,996,000 |
| Tan Thanh Packaging Company Limited | 3,189,984,930 | 3,189,984,930 | 4,815,005,322 | 4,815,005,322 |
| APC Pharmaceuticals and Chemical Limited | 7,280,928,820 | 7,280,928,820 | - | - |
| Other suppliers | 19,225,026,943 | 19,225,026,943 | 36,771,086,505 | 36,771,086,505 |
| | 33,180,387,893 | 33,180,387,893 | 64,249,230,707 | 64,249,230,707 |

5.12 Short-term advance from customers

| | 30/06/2025 VND | 01/01/2025 VND |
|--|-----------------------|-----------------------|
| Advances from other customers | | |
| Stem cell bank | 11,096,192,690 | 16,905,349,290 |
| T.N.T Pharmaceutical and Medical Equipment Joint Stock Company | 18,616,700,492 | 18,616,700,492 |
| Other customers | 16,490,951,886 | 13,283,063,690 |
| | 46,203,845,068 | 48,805,113,472 |

5.13 Taxes and (receivables), payables to State budget

| | 01/01/2025 | | Transaction in the period | | 30/06/2025 | |
|--------------------------|----------------------|----------------------|---------------------------|-----------------------------|--------------------|------------------------|
| | Payables VND | Receivables VND | Payables VND | Paid/ Deductibles VND | Payables VND | Receivables VND |
| VAT on domestic goods | - | - | 21,028,576,678 | (21,028,576,678) | - | - |
| VAT on import goods | - | (46,255,910) | 6,132,786,142 | (6,086,530,232) | - | - |
| Import tax | - | (61,529,920) | 126,004,031 | (68,783,611) | - | (4,309,500) |
| Corporate income tax | 6,346,477,406 | - | - | (9,346,477,406) | - | (3,000,000,000) |
| Personal income tax | - | - | 2,160,512,665 | (2,294,692,212) | - | (134,179,547) |
| Housing tax, land rental | - | (1,003,701) | 12,000,000,000 | (11,372,958,228) | 626,038,071 | - |
| Other taxes | 85,000,000 | (3,000,000) | 338,832,891 | (420,832,891) | - | - |
| | 6,431,477,406 | (111,789,531) | 41,786,712,407 | (50,618,851,258) | 626,038,071 | (3,138,489,047) |

Value-added tax

The Company declares value-added tax by deduction method. VAT rates for domestic goods are non-taxable, 5%, 8% and 10%.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

Corporate income tax

Corporate income tax ("CIT") payable in the period is estimated as follows:

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| Accounting profit before tax | (29,484,039,585) | 8,722,923,535 |
| Adjusted in accounting profit to determine taxable profit: | | |
| Increase adjustments | 198,906,672 | 1,117,407,481 |
| Decrease adjustments | (668,782,311) | - |
| Assessable income | (29,953,915,224) | 9,840,331,016 |
| Non-taxable income | (540,000,000) | (519,339,000) |
| Taxable income | (30,493,915,224) | 9,320,992,016 |
| CIT rate | 20% | 20% |
| Current CIT expenses | - | 1,864,198,403 |

The Parent Company and subsidiary are obliged to pay tax at the normal rate of 20% of taxable income.

Other taxes

The Company declares and pays other taxes in accordance to current regulations.

5.14 Short-term accrued expenses

| | 30/06/2025 VND | 01/01/2025 VND |
|--|----------------------|----------------------|
| Renting land expenses in the hi-tech park | 8,715,359,709 | 7,439,941,215 |
| Expenses of security and cleaning services | - | 849,083,889 |
| Electricity expenses | 192,124,768 | 155,533,638 |
| Other accrued expenses | 878,514,850 | 695,605,364 |
| | 9,785,999,327 | 9,140,164,106 |

5.15 Other short-term payables

| | 30/06/2025 VND | 01/01/2025 VND |
|--|-----------------------|-----------------------|
| Other payables - other individual, organization | | |
| Trade union, social insurance, Party fees | 150,041,080 | 149,072,080 |
| Happy House Investment Joint Stock Company (*) | 10,000,000,000 | 10,000,000,000 |
| Soviet Union Antibiotic | 118,181,818 | 118,181,818 |
| Corporate income tax (Factory 24) | 91,299,513 | 91,299,513 |
| Other payables | 727,613,247 | 650,413,247 |
| | 11,087,135,658 | 11,008,966,658 |

- (*) Payment according to the progress of cooperation with Happy House Company to implement a social housing project under the Investment Cooperation Contract No. 01/2018/HDHT dated 08 August 2018.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

5.16 Bonus and welfare funds

| | 01/01/2025 | Increase in period | Other increase | Paid in period | 30/06/2025 |
|--------------|-----------------------|-----------------------|-------------------|-------------------------|----------------------|
| | VND | VND | VND | VND | VND |
| Bonus fund | 1,521,794,766 | 3,230,180,022 | 1,410,000 | (2,184,600,000) | 2,568,784,788 |
| Welfare fund | 8,936,132,081 | 3,230,180,021 | - | (8,455,033,000) | 3,711,279,102 |
| | 10,457,926,847 | 6,460,360,043 | 1,410,000 | (10,639,633,000) | 6,280,063,890 |

5.17 Long-term unrealized revenue

| | 30/06/2025 | 01/01/2025 |
|-----------------------------------|------------------------|------------------------|
| | VND | VND |
| MekoStem unrealized revenue | 193,779,346,825 | 186,607,256,871 |
| Finished goods unrealized revenue | - | 241,120,905 |
| | 193,779,346,825 | 186,848,377,776 |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

5.18 Owner's equity

5.18.1 Owner's equity movements

| | Owners' invested capital VND | Capital surplus VND | Treasury shares VND | Investment and development funds VND | Retained earnings VND | Total VND |
|--|------------------------------------|------------------------|---------------------------|--|--------------------------|--------------------------|
| As at 01/01/2024 | 255,458,670,000 | 409,789,114,458 | (14,487,151,158) | 576,623,174,082 | 33,510,040,412 | 1,260,893,847,794 |
| Profit in the period | - | - | - | - | 6,858,725,132 | 6,858,725,132 |
| Deduction for Investment and development fund | - | - | - | 1,976,490,201 | (1,976,490,201) | - |
| Deduction for Bonus and welfare funds | - | - | - | - | (3,952,980,402) | (3,952,980,402) |
| Dividends distribution | - | - | - | - | (12,634,110,500) | (12,634,110,500) |
| Remuneration for the Board of Directors | - | - | - | - | (408,000,000) | (408,000,000) |
| As at 30/06/2024 | 255,458,670,000 | 409,789,114,458 | (14,487,151,158) | 578,599,664,283 | 21,397,184,441 | 1,250,757,482,024 |
| As at 01/07/2024 | 255,458,670,000 | 409,789,114,458 | (14,487,151,158) | 578,599,664,283 | 21,397,184,441 | 1,250,757,482,024 |
| Profit in the period | - | - | - | - | 33,926,525,139 | 33,926,525,139 |
| As at 31/12/2024 | 255,458,670,000 | 409,789,114,458 | (14,487,151,158) | 578,599,664,283 | 55,323,709,580 | 1,284,684,007,163 |
| As at 01/01/2025 | 255,458,670,000 | 409,789,114,458 | (14,487,151,158) | 578,599,664,283 | 55,323,709,580 | 1,284,684,007,163 |
| Profit in the period | - | - | - | - | (29,484,039,585) | (29,484,039,585) |
| Deduction for Investment and development fund | - | - | - | 3,230,180,022 | (3,230,180,022) | - |
| Deduction for Bonus and welfare funds | - | - | - | - | (6,460,360,043) | (6,460,360,043) |
| Dividends distribution | - | - | - | - | (12,634,110,500) | (12,634,110,500) |
| Remuneration for the Board of Directors | - | - | - | - | (408,000,000) | (408,000,000) |
| As at 30/06/2025 | 255,458,670,000 | 409,789,114,458 | (14,487,151,158) | 581,829,844,305 | 3,107,019,430 | 1,235,697,497,035 |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

5.18.2 Detail of owner's invested equity

According to the Company's the Business Registration Certificate (amended), Charter capital of the Company is VND 255,458,670,000. As at 30 June 2025, the Company's charter capital was fully contributed as follows:

| | 30/06/2025 | | | 01/01/2025 | | |
|------------------------------------|-------------------|------------------------|---------------|-------------------|------------------------|---------------|
| | Shares | Value VND | Rate % | Shares | Value VND | Rate % |
| Vietnam Pharmaceutical Corporation | 4,657,435 | 46,574,350,000 | 18.23 | 4,657,435 | 46,574,350,000 | 18.23 |
| Nipro Pharma Corporation | 3,913,140 | 39,131,400,000 | 15.32 | 3,913,140 | 39,131,400,000 | 15.32 |
| Other shareholders | 16,975,292 | 169,752,920,000 | 66.45 | 16,975,292 | 169,752,920,000 | 66.45 |
| | 25,545,867 | 255,458,670,000 | 100.00 | 25,545,867 | 255,458,670,000 | 100.00 |

5.18.3 Shares

| | 30/06/2025 Share | 01/01/2025 Share |
|-------------------------------------|---------------------|---------------------|
| Number of issued registered shares | 25,545,867 | 25,545,867 |
| Number of shares sold to the public | 25,545,867 | 25,545,867 |
| <i>Common shares</i> | 25,545,867 | 25,545,867 |
| <i>Preferred shares</i> | - | - |
| Number of repurchased shares | 277,646 | 277,646 |
| <i>Common shares</i> | 277,646 | 277,646 |
| <i>Preferred shares</i> | - | - |
| Number of shares in circulation | 25,268,221 | 25,268,221 |
| <i>Common shares</i> | 25,268,221 | 25,268,221 |
| <i>Preferred shares</i> | - | - |

Par value of shares in circulation: VND 10,000/ share.

5.18.4 Profit distribution

In the period, the Parent Company distributed dividends according to the Resolution of the Annual General Meeting of Shareholders No. 61/NQ-DHDCD dated 24 April 2025 with the value of 5% par value.

In addition, the Parent Company distributed profit of 2024 according the Resolution of the Annual General Meeting of Shareholders No. 61/NQ-DHDCD dated 24 April 2025 as follows:

| | VND |
|--|-----------------|
| - Deduct 8% from retained earnings of 2024 for Investment and development fund | : 3,230,180,022 |
| - Deduct 16% from retained earnings of 2024 for Bonus and welfare funds | : 6,460,360,043 |

5.19 Off-consolidated balance sheet items

Foreign currency

| | 30/06/2025 Foreign currency | 01/01/2025 Foreign currency |
|-----------------|--------------------------------|--------------------------------|
| US Dollar (USD) | 28,672.38 | 31,312.24 |
| Euro (EUR) | 858.59 | 862.80 |
| Japan Yen (JPY) | 36,793,981.00 | 107,213,146.00 |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

6. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE CONSOLIDATED INCOME STATEMENT

6.1 Revenues from sale of goods and rendering of services

6.1.1 Net revenues

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---------------------------------------|---|---|
| Revenue from sale of finished goods | 384,856,436,898 | 426,789,756,206 |
| Revenue from sale of goods | 205,009,513 | 63,480,004 |
| Revenue from stem cell bank service | 34,242,805,671 | 37,307,268,524 |
| Revenue from sale of materials, other | 2,420,268,423 | 796,467,400 |
| Revenue from rental | 5,565,000,000 | 4,932,000,000 |
| Deduction: | | |
| Returned goods | (92,845,934) | - |
| Net revenues | 427,196,674,571 | 469,888,972,134 |

6.1.2 Revenue from sale of goods and rendering of services to related parties

Transactions of sales of goods and rendering of services to related parties are as follows:

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| Nipro Pharma Corporation | 4,945,791,864 | 8,033,851,221 |
| An Sinh Hospital Joint Stock Company | 5,157,253,090 | 5,164,898,650 |
| Orchids Trading Service Travel Company Limited | 1,425,000,000 | 792,000,000 |
| | 11,528,044,954 | 13,990,749,871 |

6.2 Cost of sales

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---|---|---|
| Cost of finished goods sold | 311,228,113,353 | 318,008,429,601 |
| Cost of goods sold | 184,661,914 | 59,507,389 |
| Cost of stem cell bank service | 10,501,445,530 | 11,368,355,636 |
| Cost of materials sold, rendering of services | 1,563,295,673 | 781,598 |
| Provision for devaluation of inventories | - | 2,808,421,803 |
| | 323,477,516,470 | 332,245,496,027 |

6.3 Financial income

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| Interest from deposit | 2,193,331,178 | 1,808,846,594 |
| Dividends, distributed profit | 540,000,000 | 519,339,000 |
| Foreign exchange gain | 1,177,853,089 | 91,559,454 |
| Foreign exchange gain due to the revaluation of monetary items denominated in foreign currencies | 486,300,466 | - |
| | 4,397,484,733 | 2,419,745,048 |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

6.4 Financial expenses

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| Foreign exchange loss | 1,654,719,131 | 2,511,814,476 |
| Foreign exchange loss due to the revaluation of monetary items denominated in foreign currencies | - | 913,898,567 |
| | 1,654,719,131 | 3,425,713,043 |

6.5 Selling expenses

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|-------------------------|---|---|
| Labor expenses | 11,574,771,576 | 13,082,054,432 |
| Depreciation expenses | 165,798,630 | 165,798,630 |
| Service expense | 25,147,055,054 | 22,396,720,206 |
| Marketing expenses | 18,194,327,456 | 20,403,647,695 |
| Transportation expenses | 1,116,943,333 | 2,468,100,353 |
| Other selling expenses | 199,393,683 | 139,920,640 |
| | 56,398,289,732 | 58,656,241,956 |

6.6 General and administration expenses

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---|---|---|
| Labor expenses | 23,021,902,640 | 23,583,436,901 |
| Tools and equipment expenses | 10,771,873,017 | 2,009,364,588 |
| Depreciation expenses | 6,235,392,306 | 6,244,676,196 |
| Tax and fees | 13,377,430,091 | 13,565,368,242 |
| Provision expenses | 170,873,389 | 3,617,407,481 |
| Service expenses | 6,822,888,510 | 7,785,419,635 |
| Other general and administration expenses | 19,457,945,747 | 12,076,781,374 |
| | 79,858,305,700 | 68,882,454,417 |

6.7 Other incomes

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|------------------------------------|---|---|
| Gain from disposal of fixed assets | 22,727,273 | - |
| Income from stock count | 336,950,883 | 44,106,452 |
| Donated materials | 632,090 | 628,390 |
| | 360,310,246 | 44,734,842 |

6.8 Other expenses

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|------------------------------------|---|---|
| Loss from disposal of fixed assets | - | 384,999,274 |
| Expenses from stock count | 49,678,102 | 10,225,632 |
| Other expenses | - | 25,398,140 |
| | 49,678,102 | 420,623,046 |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

6.9 Basic earnings per share

The calculation of basic earnings per share attributable to shareholders holding common shares of the Parent Company are made on the basis of the following data:

| | | From 01/01/2025 to 30/06/2025 | From 01/01/2024 to 30/06/2024 |
|--|-----------|----------------------------------|----------------------------------|
| Profit for the year attributable to shareholders holding common shares of the Parent Company | VND | (29,484,039,585) | 6,858,725,132 |
| Deduction: bonus and welfare funds | VND | - | - |
| Profit to calculate EPS | VND | (29,484,039,585) | 6,858,725,132 |
| Outstanding common shares on average during the year | share | 25,268,221 | 25,268,221 |
| Earnings per share | VND/share | (1,167) | 271 |

(*) The Parent Company has not planned to deduct the bonus and welfare fund on the profit after tax at the time of preparing the financial statements for the six-month period ended 30 June 2025.

6.10 Production and business costs by element

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---------------------------|---|---|
| Raw materials expenses | 289,505,692,887 | 294,606,874,914 |
| Labor expenses | 60,443,397,687 | 63,421,289,919 |
| Depreciation expenses | 23,553,752,420 | 23,797,449,648 |
| External service expenses | 43,318,956,666 | 42,652,831,342 |
| Other expenses | 53,300,039,508 | 52,137,799,778 |
| | 470,121,839,168 | 476,616,245,601 |

7. FINANCIAL INSTRUMENTS

The Company has financial assets such as customer receivables and other receivables, cash and short-term deposits that occur directly from the operations of the Company. Financial liabilities of the Company mainly include loans, payables to suppliers and other payables. The main purpose of these financial liabilities is to mobilize financial resources to serve the activities of the Company.

The Company has market risk, credit risk and liquidity risk.

Operational risk management is indispensable operations for the entire operations of the Company. The Company has developed control system to ensure balance between the extent reasonable costs incurred when risk and risk management costs. The Company has not implemented measures to prevent this risk due to lack of a market to purchase financial instruments.

The Board of General Directors considered and uniformly applies policies to manage each of these risks are summarized below:

i. Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk has four types of risk: interest rate risk, currency risk, goods price risk and other price risk, such as equity price risk.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Market risk for changes in interest rates of the Company primarily relating to cash, short term deposits, and loans of the Company.

The Company is managing interest rate risk by analyzing the competitive situation in the market to acquire beneficial interest for the purposes of the Company and remain within the limits of their risk management.

Foreign currency risk

Foreign currency risk is the risk that the fair value of the future cash flows of a financial instrument will fluctuate because of changes in exchange rates. The Company bears the risk of changes in exchange rates, which are directly related to the business operations of the Company.

Stock price risk

The shares held by the Company are affected by market risks arising from uncertainty about the future value of the investment shares. The company manages stock price risk by setting investment limits. The Board of General Directors also reviews and approves investment decisions in shares. The Company considers the share price risk to be negligible.

ii. Credit risk

Credit risk is the risk that one party of a financial instrument or contract not performing its obligations, resulting in financial losses. The Company has credit risk from its operating activities (primarily for trade receivables account), and from its financial activities, including bank deposits and other financial instruments.

Trade receivables

The Company regularly monitors the receivables, which is not yet collected. For big customers, the Company considered the decline in the credit quality of each customer at the reporting date. The Company seeks the way to remained the tight control of the receivables and arranging credit control staff to minimize credit risk. On this basis and the trade receivables of the Company related to many different customers, credit risk is not significantly concentrated in a certain customer.

Cash in bank

The Company mainly maintains deposit balances at banks, which is well known in Vietnam. Credit risk of the deposit balances at banks is managed by the treasury department of the Company under the policies of the Company. The maximum credit risk of the Company for the items on the balance sheet at the end of the financial year is the value book as presented in Note 5.1. The Company found that the level of concentration of credit risk on bank deposits is low.

iii. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulties in implementing their financial obligations due to lack of funds. Liquidity risk of the Company mainly arising from financial assets and financial liabilities with maturity mismatches.

The Company minimizes the liquidity risk by maintaining an amount of cash and cash equivalents and bank loans at a level that the Board of General Directors supposes it is sufficient to meet the Company's operations and minimize the risks due to the volatility of cash flows.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

The table below summarizes the maturity of the financial liabilities of the Company based on expected payments on undiscounted basic contracts:

| | Less than 1 year VND | From 1 to 5 years VND | Total VND |
|------------------------------|----------------------------|-----------------------------|-----------------------|
| As at 30 June 2025 | | | |
| Trade payables | 33,180,387,893 | - | 33,180,387,893 |
| Accrued expenses | 9,785,999,327 | - | 9,785,999,327 |
| Other payables | 10,937,094,578 | - | 10,937,094,578 |
| | 53,903,481,798 | - | 53,903,481,798 |
| As at 01 January 2025 | | | |
| Trade payables | 64,249,230,707 | - | 64,249,230,707 |
| Accrued expenses | 9,140,164,106 | - | 9,140,164,106 |
| Other payables | 10,859,894,578 | - | 10,859,894,578 |
| | 84,249,289,391 | - | 84,249,289,391 |

The Company considered that the level of concentration risk to the repayment is low. The Company has sufficient access to the necessary capital.

iv. Fair value

(1) Compare fair value and book value

The following table showing the financial assets and financial liabilities of the Company:

| | Book value | | Fair value (*) | |
|--|------------------------|------------------------|------------------------|------------------------|
| | 30/06/2025 VND | 01/01/2025 VND | 30/06/2025 VND | 01/01/2025 VND |
| Financial assets | | | | |
| Held-to-maturity investments | 20,000,000,000 | 45,000,000,000 | 20,000,000,000 | 45,000,000,000 |
| Loans and Accounts Receivable | | | | |
| Trade receivables | 47,619,764,513 | 51,199,264,078 | 36,938,014,695 | 40,649,415,201 |
| Other receivables | 11,746,614,713 | 1,084,511,083 | 11,738,505,513 | 1,076,401,883 |
| Financial assets available for sale | | | | |
| Short-term financial investments | 10,946,711,100 | 10,946,711,100 | 10,946,711,100 | 10,946,711,100 |
| Long-term financial investments | 24,068,960,000 | 24,068,960,000 | 24,068,960,000 | 24,068,960,000 |
| Cash and cash equivalents | 85,920,852,776 | 173,723,141,505 | 85,920,852,776 | 173,723,141,505 |
| | 200,302,903,102 | 306,022,587,766 | 189,613,044,084 | 295,464,629,689 |
| Financial liabilities | | | | |
| Financial liabilities are determined according to the distribution value | | | | |
| Trade payables | 33,180,387,893 | 64,249,230,707 | 33,180,387,893 | 64,249,230,707 |
| Accrued expenses | 9,785,999,327 | 9,140,164,106 | 9,785,999,327 | 9,140,164,106 |
| Other payables | 10,937,094,578 | 10,859,894,578 | 10,937,094,578 | 10,859,894,578 |
| | 53,903,481,798 | 84,249,289,391 | 53,903,481,798 | 84,249,289,391 |

(*) The Company has not revaluated its financial assets and financial liabilities at their fair values as at 30 June 2025 and 01 January 2025. However, the Board of General Directors believes that the fair value of these financial assets and liabilities is not significantly different from their carrying amounts as at the balance sheet date.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

(2) Basis of determining fair value

Accounts receivable and other receivables

The fair value of accounts receivables and other receivables, excluding accounts receivable and payable under the scheduled progress of construction contracts, is estimated based on the present value of cash flows future, discounted at market interest rates at the report date. The fair value of these instruments is determined only intended disclosures.

Non-derivative financial liabilities

Fair value, measured for disclosure purposes only, is calculated based on the present value of future cash flows to pay principal and interest, discounted at market rates at the balance sheet date.

8. OTHER INFORMATION

8.1 Transactions and balances with related parties

The related parties with the Company include key members of management, the individuals involved with key members and other related parties.

8.1.1. Transactions and balances with key members, the individuals involved with key members

Remuneration paid to key management members during the period was as follow:

| | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|--|---|---|
| Salary and bonus | | |
| Mr. Le Anh Phuong | 784,160,888 | 812,877,177 |
| Ms. Huynh Thi Lan | 1,195,563,745 | 1,208,468,267 |
| Ms. Dang Thi Kim Lan | 687,575,486 | 755,388,066 |
| Ms. Phan Thi Lan Huong (appointed on 07/05/2025) | 1,312,112,673 | 1,068,985,486 |
| Mr. Satoshi Kawamura (resigned on 24/04/2025) | 48,000,000 | 72,000,000 |
| Ms. Nguyen Thi Quynh Anh (resigned on 24/04/2025) | 315,220,401 | 453,465,850 |
| Mr. Dinh Xuan Han | - | 51,000,000 |
| Ms. Lu Thi Khanh Tran (resigned on 24/04/2025) | 48,000,000 | 24,000,000 |
| Ms. Nguyen Thi Hang (appointed on 24/04/2025) | 24,000,000 | - |
| | 4,414,633,193 | 4,446,184,846 |

8.1.2 Transactions and balances with other related parties

Significant transactions with related parties in the period are as follows:

| Related parties | Transaction | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---------------------------------|------------------------|---|---|
| Nipro Pharma Corporation | | | |
| | Sale of finished goods | 4,945,791,864 | 8,033,851,221 |
| | Buy raw materials | 856,052,129 | 855,228,768 |
| | Donated raw materials | 632,090 | 628,390 |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

| Related parties | Transaction | From 01/01/2025 to 30/06/2025 VND | From 01/01/2024 to 30/06/2024 VND |
|---|-----------------------------|---|---|
| An Sinh Hospital Joint Stock Company | | | |
| | Sales and services rendered | 5,157,253,090 | 5,164,898,650 |
| Orchids Trading Service Travel Company Limited | | | |
| | Sales and services rendered | 1,425,000,000 | 792,000,000 |

As at 30 June 2025, the balance of accounts receivable/ payable with related parties is as follows:

| Related parties | Transaction | 30/06/2025 VND | 01/01/2025 VND |
|---|-------------------|-------------------|-------------------|
| Nipro Pharma Corporation | | | |
| | Trade receivables | 4,904,812,357 | - |
| | Trade payables | - | 855,467,480 |
| An Sinh Hospital Joint Stock Company | | | |
| | Trade receivables | 353,467,528 | 216,144,129 |
| Orchids Trading Service Travel Company Limited | | | |
| | Trade receivables | 1,567,500,000 | - |

8.2 Segment information

Segment information by operating activities

- a. Segment income statement operating activities for the six-month period ended 30 June 2025:

| Items | Net revenue VND | Cost VND | Gross profit VND |
|------------------------|------------------------|------------------------|------------------------|
| Finished goods | 384,763,590,964 | 311,228,113,353 | 73,535,477,611 |
| Goods | 205,009,513 | 184,661,914 | 20,347,599 |
| Stem cell bank service | 34,242,805,671 | 10,501,445,530 | 23,741,360,141 |
| Materials | 2,420,268,423 | 1,563,295,673 | 856,972,750 |
| Rental | 5,565,000,000 | - | 5,565,000,000 |
| Total | 427,196,674,571 | 323,477,516,470 | 103,719,158,101 |

- b. Segment income statement operating activities for the six-month period ended 30 June 2024:

| Items | Net revenue VND | Cost VND | Gross profit VND |
|------------------------|------------------------|------------------------|------------------------|
| Finished goods | 426,789,756,206 | 320,816,851,404 | 105,972,904,802 |
| Goods | 63,480,004 | 59,507,389 | 3,972,615 |
| Stem cell bank service | 37,307,268,524 | 11,368,355,636 | 25,938,912,888 |
| Materials | 796,467,400 | 781,598 | 795,685,802 |
| Rental | 4,932,000,000 | - | 4,932,000,000 |
| Total | 469,888,972,134 | 332,245,496,027 | 137,643,476,107 |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the six-month period ended 30 June 2025


These notes form an integral part of and should be read in conjunction with the accompanying interim consolidated financial statements.

Segment information by geographical area

The Company does not present segment information by geographical area, because all activities take place in the only geographical area, which is Vietnam.

8.3 Events subsequent to the balance sheet date

There have been no significant events occurring after the balance sheet date (30 June 2025) to the date of this report, which would require adjustments or disclosures to be made in the interim consolidated financial statements.



LE THI THU HUONG
Preparer



PHAN ANH TAI
Chief Accountant



PHAN THI LAN HUONG
General Director

Ho Chi Minh City, 22 August 2025

